Noninvasive detection of carboxypeptidase G2 activity in vivo

NMR in Biomedicine

Volumn 24, Issue 4, 2011, Pages 343-350

  Jamin, Yann ^a   Smyth, Lynette ^a   Robinson, Simon P ^a   Poon, Evon S C ^a   Eykyn, Thomas R ^a   Springer, Caroline J ^a   Leach, Martin O ^a   Payne, Geoffrey S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

19F MRS; Biomarker; CPG2; Gene therapy; Molecular imaging

Indexed keywords

19F MRS; ACID CONCENTRATIONS; ACTIVITY LEVELS; CARBOXYPEPTIDASE; CLINICAL DEVELOPMENT; CPG2; HIGH SIGNAL-TO-NOISE RATIO; HUMAN COLON; IN-VIVO; MOLECULAR IMAGING; NEW APPLICATIONS; NON-INVASIVE DETECTION; NON-INVASIVE IMAGING; PRODRUGS; RATE OF INCREASE; TARGETED CHEMOTHERAPY; TRANSGENE EXPRESSION; TREATMENT RESPONSE;

AMINO ACIDS; CHEMICAL DETECTION; CHEMOTHERAPY; ENZYMES; FADING (RADIO); FLUORINE; GENE EXPRESSION; GENETIC ENGINEERING; PATIENT TREATMENT; PROBES; SIGNAL TO NOISE RATIO; TUMORS;

GENE THERAPY;

3,5 DIFLUOROBENZOIC ACID; 3,5 DIFLUOROBENZOYL GLUTAMIC ACID; BENZOIC ACID DERIVATIVE; BIOLOGICAL MARKER; CARBOXYPEPTIDASE G2; FLUORINE; GLUTAMIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; FLUORINE NUCLEAR MAGNETIC RESONANCE; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MEDIATOR; MOLECULAR DYNAMICS; MOLECULAR PROBE; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTON NUCLEAR MAGNETIC RESONANCE; REPORTER GENE; SIGNAL NOISE RATIO; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; BENZOIC ACID; CELL LINE, TUMOR; FEMALE; FLUORINE; GAMMA-GLUTAMYL HYDROLASE; GLUTAMIC ACID; HUMANS; MICE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959595736     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1597     Document Type: Article

References (35)

1. Rowsell S, Pauptit RA, Tucker AD, Melton RG, Blow DM, Brick P. Crystal structure of carboxypeptidase G2, a bacterial enzyme with applications in cancer therapy. Structure, 1997; 5(3): 337-347.
2. Niculescu-Duvaz D, Niculescu-Duvaz I, Springer CJ. Design of prodrugs for suicide gene therapy. Methods Mol. Med. 2004; 90: 161-202.
3. Hedley D, Ogilvie L, Springer C. Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury. Nat. Rev. Cancer, 2007; 7(11): 870-879.
4. Mayer A, Francis RJ, Sharma SK, Tolner B, Springer CJ, Martin J, Boxer GM, Bell J, Green AJ, Hartley JA, Cruickshank C, Wren J, Chester KA, Begent RH. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. Clin. Cancer Res. 2006; 12(21): 6509-6516.
5. Schepelmann S, Ogilvie LM, Hedley D, Friedlos F, Martin J, Scanlon I, Chen P, Marais R, Springer CJ. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase g2. Cancer Res. 2007; 67(10): 4949-4955.
6. Friedlos F, Lehouritis P, Ogilvie L, Hedley D, Davies L, Bermudes D, King I, Martin J, Marais R, Springer CJ. Attenuated salmonella targets prodrug activating enzyme carboxypeptidase g2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy. Clin. Cancer Res. 2008; 14(13): 4259-4266.
7. Presant CA, Wolf W, Waluch V, Wiseman C, Kennedy P, Blayney D, Brechner RR. Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet, 1994; 343(8907): 1184-1187.
8. 19F-MRS studies of fluorinated drugs in humans. Adv. Drug Deliv. Rev. 2000; 41(1): 55-74.
9. Aboagye EO, Artemov D, Senter PD, Bhujwalla ZM. Intratumoral conversion of 5-fluorocytosine to 5-fluorouracil by monoclonal antibody-cytosine deaminase conjugates: noninvasive detection of prodrug activation by magnetic resonance spectroscopy and spectroscopic imaging. Cancer Res. 1998; 58(18): 4075-4078.
10. Stegman LD, Rehemtulla A, Beattie B, Kievit E, Lawrence TS, Blasberg RG, Tjuvajev JG, Ross BD. Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. USA, 1999; 96(17): 9821-9826.
11. Gade TP, Koutcher JA, Spees WM, Beattie BJ, Ponomarev V, Doubrovin M, Buchanan IM, Beresten T, Zakian KL, Le HC, Tong WP, Mayer-Kuckuk P, Blasberg RG, Gelovani JG. Imaging transgene activity in vivo. Cancer Res. 2008; 68(8): 2878-2884.
12. 19F-NMR detection of lacZ gene expression via the enzymic hydrolysis of 2-fluoro-4-nitrophenyl beta-D-galactopyranoside in vivo in PC3 prostate tumor xenografts in the mouse. Faseb J 2007; 21(9): 2014-2019.
13. Mancini L, Davies L, Friedlos F, Falck-Miniotis M, Dzik-Jurasz AS, Springer CJ, Leach MO, Payne GS. A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using (19)F magnetic resonance spectroscopy. NMR Biomed. 2009; 22: 561-566.
14. Rovati L, Makovec F, Chiste R, Senin P. Derivatives of glutamic acid and aspartic acid. US Patent No. 4, 791, 215, 1988; (granted 13 December 1988).
15. Marais R, Spooner RA, Stribbling SM, Light Y, Martin J, Springer CJ. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nat. Biotechnol. 1997; 15(13): 1373-1377.
16. Spooner RA, Martin J, Friedlos F, Marais R, Springer CJ. In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug. Cancer Gene Ther. 2000; 7(10): 1348-1356.
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 1983; 65(1-2): 55-63.
18. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br. J. Cancer, 1998; 77: 1-10.
19. 31P NMR signals using the variable projection method and prior knowledge. Magn. Reson. Med. 1988; 6(1): 92-98.
20. 19F MR spectroscopy at 3 T to detect heterogeneous capecitabine metabolism in human liver. NMR Biomed. 2007; 20(5): 485-492.
21. Schepelmann S, Spooner R, Friedlos F, Marais R. Methods to improve efficacy in suicide gene therapy approaches: targeting prodrug-activating enzymes carboxypeptidase G2 and nitroreductase to different subcellular compartments. Methods Mol. Med. 2004; 90: 279-301.
22. 19F MRS detection of carboxypeptidase G2 activity. Proceedings 16th Annual Meeting ISMRM, Toronto, ON, Canada, 2008; 657.
23. 1H-NMR spectroscopy. NMR Biomed. 2002; 15(1): 37-44.
24. Pedley RB, Sharma SK, Boxer GM, Boden R, Stribbling SM, Davies L, Springer CJ, Begent RH. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res. 1999; 59(16): 3998-4003.
25. Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ, Martin J, Stribbling SM, Cushen N, O'Malley D, Begent RH. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin. Cancer Res. 2000; 6(3): 765-772.
26. Schepelmann S, Hallenbeck P, Ogilvie LM, Hedley D, Friedlos F, Martin J, Scanlon I, Hay C, Hawkins LK, Marais R, Springer CJ. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Cancer Res. 2005; 65(12): 5003-5008.
27. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat. Rev. Cancer, 2006; 6(8): 583-592.
28. Ellis RJ. Macromolecular crowding: obvious but underappreciated. Trends Biochem. Sci. 2001; 26(10): 597-604.
29. Minton AP. The influence of macromolecular crowding and macromolecular confinement on biochemical reactions in physiological media. J. Biol. Chem. 2001; 276(14): 10, 577-10, 580.
30. Kasuya F, Yamaoka Y, Osawa E, Igarashi K, Fukui M. Difference of the liver and kidney in glycine conjugation of ortho-substituted benzoic acids. Chem. Biol. Interact. 2000; 125(1): 39-50.
31. Bray HG, Thorpe WV, Wood PB. The fate of certain organic acids and amides in the rabbit. 12. Aminohydroxybenzoic acids. Biochem. J. 1951; 48(4): 394-399.
32. Brakefield JL. Detoxification of benzoic acid in man. J. Biol. Chem. 1927; 74(3): 783-785.
33. Carter EL, Jager L, Gardner L, Hall CC, Willis S, Green JM. Escherichia coli abg genes enable uptake and cleavage of the folate catabolite p-aminobenzoyl-glutamate. J. Bacteriol. 2007; 189(9): 3329-3334.
34. Steele M, Marcone M, Gyles C, Chan VL, Odumeru J. Enzymatic activity of Campylobacter jejuni hippurate hydrolase. Protein Eng. Des. Sel. 2006; 19(1): 17-25.
35. Valerino DM, Johns DG, Zaharko DS, Oliverio VT. Studies of the metabolism of methotrexate by intestinal flora. I. Identification and study of biological properties of the metabolite 4-amino-4-deoxy-N10-methylpteroic acid. Biochem. Pharmacol. 1972; 21(6): 821-831.